{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-186853","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2023-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.916344+00:00","generated_at":"2026-06-13T08:14:56.788940+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Frequency Therapeutics to merge with Korro Bio in all-stock deal; combined firm to focus on RNA editing, trade as KRRO","bullets":["Pre-merger Frequency stockholders expected to own ~8% of combined company; Korro stockholders (incl. new investors) ~92%.","Korro Bio secures $117M concurrent private financing co-led by Surveyor Capital and Cormorant; pro-forma cash ~$170M at close.","Lead program: RNA editing therapy for AATD; preclinical data shows correction to 85% normal A1AT protein; IND planned H2 2024.","Frequency discontinues its MS remyelination program; stockholders may receive CVR for future proceeds from that program.","Merger expected to close Q4 2023, subject to Frequency stockholder approval; combined company led by Korro management."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-186853","json":"https://secwatch.observer/filing/0001193125-23-186853.json","markdown":"https://secwatch.observer/filing/0001193125-23-186853.md","text":"https://secwatch.observer/filing/0001193125-23-186853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523186853/0001193125-23-186853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523186853/d529859d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:14:56.788940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}